Brentuximab Vedotin + CHP for T-Cell Lymphoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymphoma (PTCL). It will also find out what side effects occur when brentuximab vedotin and CHP are used together. A side effect is anything the drugs do besides treating cancer. CHP is a type of chemotherapy that uses three drugs (cyclophosphamide, doxorubicin, and prednisone). CHP is approved by the FDA to treat certain types of PTCL.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What makes the drug Brentuximab Vedotin + CHP unique for treating T-cell lymphoma?
Brentuximab Vedotin + CHP is unique because it specifically targets CD30-positive T-cell lymphomas, offering improved outcomes compared to traditional treatments like CHOP. It has become the new standard for first-line treatment in certain types of T-cell lymphomas, providing a new option for patients with these challenging conditions.12345
What data supports the effectiveness of the drug Brentuximab Vedotin plus CHP for T-cell lymphoma?
The ECHELON-2 trial showed that Brentuximab Vedotin combined with cyclophosphamide, doxorubicin, and prednisone (A+CHP) improved outcomes compared to the standard treatment for CD30-positive peripheral T-cell lymphomas. This combination was found to be practice-changing for common nodal CD30+ PTCLs, indicating its effectiveness.12567
Who Is on the Research Team?
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Are You a Good Fit for This Trial?
This trial is for adults with specific types of peripheral T-cell lymphoma (PTCL) that express less than 10% CD30. Eligible participants include those newly diagnosed with PTCL, excluding systemic anaplastic large cell lymphoma, and have a performance status allowing daily activity. People who've had certain prior cancer treatments or have severe pre-existing conditions are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive brentuximab vedotin with CHP for the treatment of PTCL
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Brentuximab Vedotin
- Cyclophosphamide
- Doxorubicin
- Prednisone
Brentuximab Vedotin is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Seagen, a wholly owned subsidiary of Pfizer
Lead Sponsor
Seagen Inc.
Lead Sponsor
Dr. Roger Dansey
Seagen Inc.
Chief Medical Officer since 2018
MD from University of Witwatersrand
David R. Epstein
Seagen Inc.
Chief Executive Officer since 2022
BSc in Pharmacy from Rutgers University, MBA from Columbia University